SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIO CEO & Investor Conference on February 12, 2008 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. David A. Walsey, Arena's Director of Corporate Communications, is scheduled to provide an overview of the company, including its clinical development and discovery programs.
A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, internal and
partnered programs, and ability to develop compounds and commercialize
drugs. For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results may
differ materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking statements
include, but are not limited to, planned clinical trials and studies may
not proceed at the time or in the manner Arena expects or at all, the
results of preclinical studies or clinical trials may not be predictive of
future results, Arena's ability to partner lorcaserin, APD125, APD791 or
other of its compounds or programs, the timing, success and cost of Arena's
research, out-licensing endeavors and clinical trials, Arena's ability to
obtain additional financing, Arena's ability to obtain and defend its
patents, and the timing and receipt of payments and fees, if any, from
Arena's collaborators. Additional factors that could cause actual results
to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements
represent Arena's judgment as of the time of this release. Arena disclaims
any intent or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Contacts: Jack Lief Mary Claire Duch
President and CEO WeissComm Partners
David Walsey 212.301.7228
Director, Corporate Communications
Arena Pharmaceuticals, Inc.
858.453.7200, ext. 1682
|SOURCE Arena Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved